DE69233643D1 - Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose - Google Patents

Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose

Info

Publication number
DE69233643D1
DE69233643D1 DE69233643T DE69233643T DE69233643D1 DE 69233643 D1 DE69233643 D1 DE 69233643D1 DE 69233643 T DE69233643 T DE 69233643T DE 69233643 T DE69233643 T DE 69233643T DE 69233643 D1 DE69233643 D1 DE 69233643D1
Authority
DE
Germany
Prior art keywords
anticytokin
therapy
pharmaceutical compositions
multiple sclerosis
containing pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233643T
Other languages
English (en)
Other versions
DE69233643T2 (de
Inventor
David Wallach
Dan Aderka
Hartmut Engelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233643(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69233643D1 publication Critical patent/DE69233643D1/de
Application granted granted Critical
Publication of DE69233643T2 publication Critical patent/DE69233643T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69233643T 1991-05-07 1992-05-07 Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose Expired - Lifetime DE69233643T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL9807891 1991-05-07
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne

Publications (2)

Publication Number Publication Date
DE69233643D1 true DE69233643D1 (de) 2006-09-14
DE69233643T2 DE69233643T2 (de) 2007-07-26

Family

ID=11062415

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69229975T Expired - Lifetime DE69229975T2 (de) 1991-05-07 1992-05-07 Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten
DE69233643T Expired - Lifetime DE69233643T2 (de) 1991-05-07 1992-05-07 Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69229975T Expired - Lifetime DE69229975T2 (de) 1991-05-07 1992-05-07 Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten

Country Status (12)

Country Link
EP (2) EP0880970B1 (de)
JP (1) JP3320774B2 (de)
AT (2) ATE184488T1 (de)
AU (1) AU1609492A (de)
CA (1) CA2068027C (de)
DE (2) DE69229975T2 (de)
DK (2) DK0512528T3 (de)
ES (2) ES2137935T3 (de)
GR (1) GR3031805T3 (de)
IL (1) IL98078A0 (de)
PT (1) PT880970E (de)
ZA (1) ZA923310B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
JPH09509646A (ja) * 1993-07-30 1997-09-30 ケネディー インスティチュート オブ リューマトロジー 多発性硬化症を治療する方法
HUT76666A (en) * 1994-07-22 1997-10-28 Hoffmann La Roche Pharmaceutical compositions comprising a chimaeric tnf binding protein
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
DE69525181T2 (de) * 1995-07-14 2002-08-14 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2273850A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP2002846B1 (de) 1996-12-06 2017-01-25 Amgen Inc. Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7674453B2 (en) * 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE69017753T3 (de) * 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
DE69022559T2 (de) * 1989-12-13 1996-05-02 Yeda Res & Dev Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
ATE190629T1 (de) * 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DK0512528T3 (da) 1999-12-20
JP3320774B2 (ja) 2002-09-03
EP0880970A1 (de) 1998-12-02
CA2068027A1 (en) 1992-11-08
DK0880970T3 (da) 2006-11-20
ES2137935T3 (es) 2000-01-01
GR3031805T3 (en) 2000-02-29
DE69229975T2 (de) 2000-05-11
EP0512528B1 (de) 1999-09-15
ATE334695T1 (de) 2006-08-15
EP0512528A2 (de) 1992-11-11
DE69233643T2 (de) 2007-07-26
CA2068027C (en) 2003-09-23
EP0880970B1 (de) 2006-08-02
PT880970E (pt) 2006-12-29
EP0512528A3 (en) 1993-07-21
ATE184488T1 (de) 1999-10-15
AU1609492A (en) 1992-11-12
IL98078A0 (en) 1992-06-21
JPH05170661A (ja) 1993-07-09
DE69229975D1 (de) 1999-10-21
ZA923310B (en) 1993-01-27
ES2270479T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
DE69233643D1 (de) Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose
ATE535255T1 (de) Anti-tnf antikörper und methotrexat zur gleichzeitigen behandlung von autoimmunkrankheiten
EP0787802A3 (de)
NO943617D0 (no) Fusjonsproteiner omfattende tumornekrosefaktor-reseptor
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
FI900808A0 (fi) Humant mannos bindande protein.
ATE237638T1 (de) Rekombinante antikörper zur humanen therapie
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE69017825D1 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
AU673835B2 (en) Medicinal composition comprising TCF-II
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 880970

Country of ref document: EP